Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AADvac1 | Axon peptide 108 conjugated to KLH | Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) | Axon Neuroscience SE | Tau | Immunotherapy (active) | |
| ACI-35 | VAC20121, JNJ-64042056 |
Alzheimer's Disease (Phase 2/3) | AC Immune SA, Janssen | Tau | Immunotherapy (active) | |
| ACI-3024 | Tau MorphomerTM | Alzheimer's Disease (Inactive), Other Tauopathy (Phase 0) | AC Immune SA | Tau | Small Molecule | |
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| ASN51 | ASN121151 | Alzheimer's Disease (Phase 1) | Asceneuron SA | Tau | Small Molecule | |
| ASN90 | ASN120290, ASN-561 |
Progressive Supranuclear Palsy (Phase 1) | Asceneuron SA | Tau | Small Molecule | |
| AV-1980R/A | AV-1980R | Alzheimer's Disease (Phase 1) | Tau | Immunotherapy (active) | ||
| Bepranemab | UCB0107 , UCB 0107 , Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BIIB076 | NI-105, 6C5 huIgG1/l |
Alzheimer's Disease (Discontinued) | Biogen, Eisai Co., Ltd., Neurimmune | Tau | Immunotherapy (passive) | |
| BIIB080 | IONIS-MAPTRx, ISIS 814907 |
Alzheimer's Disease (Phase 1) | Biogen, IONIS Pharmaceuticals | Tau | DNA/RNA-based | |
| BIIB113 | Alzheimer's Disease (Phase 1) | Biogen | Tau | Small Molecule | ||
| BMS-986446 | PRX005 | Alzheimer's Disease (Phase 2) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
| Ceperognastat | LY3372689 | Alzheimer's Disease (Phase 2) | Eli Lilly & Co. | Tau | Small Molecule | |
| Dasatinib + Quercetin | Alzheimer's Disease (Phase 1/2) | Tau, Other | Combination, Small Molecule, Supplement, Dietary | |||
| Davunetide | NAP, AL-108 |
Mild Cognitive Impairment (Discontinued), Progressive Supranuclear Palsy (Discontinued), Schizophrenia (Discontinued), Frontotemporal Dementia (Inactive) | Allon Therapeutics Inc., Paladin Labs Inc. | Tau | Other | |
| E2814 | Alzheimer's Disease (Phase 1/2) | Eisai Co., Ltd. | Tau | Immunotherapy (passive) | ||
| Efavirenz | Efavirenz | Alzheimer's Disease (Phase 1) | Amyloid-Related, Tau, Cholesterol | Small Molecule | HIV infection | |
| Emrusolmin | Anle138b, TEV-56286 |
Parkinson's Disease (Phase 1/2), Multiple System Atrophy (Phase 2) | MODAG GmbH, Teva | Tau, alpha-synuclein, Other | Small Molecule | |
| Epothilone D | BMS-241027 | Alzheimer's Disease (Discontinued) | Bristol-Myers Squibb | Tau | Small Molecule | |
| Ezeprogind | AZP2006 , AZP-2006 |
Progressive Supranuclear Palsy (Phase 2) | AlzProtect | Tau, Inflammation, Other | Small Molecule | |
| Gosuranemab | BIIB092, BMS-986168, IPN007 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | Biogen, Bristol-Myers Squibb | Tau | Immunotherapy (passive) | |
| HMTM | LMTM, LMTX, LMT-X, TRx0237, Tau aggregation inhibitor (TAI), Methylene Blue |
Alzheimer's Disease (Phase 3), Frontotemporal Dementia (Phase 3) | TauRx Therapeutics Ltd | Tau | Small Molecule | Methylene Blue predates FDA. Used for treatment of malaria and methemoglobinemia. |
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| LY3954068 | Alzheimer's Disease (Phase 1) | Eli Lilly & Co. | Tau | DNA/RNA-based | ||
| MK-2214 | Alzheimer's Disease (Phase 1) | Merck | Tau | Immunotherapy (passive) | ||
| NIO752 | Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) | Novartis Pharmaceuticals Corporation | Tau | DNA/RNA-based | ||
| OLX-07010 | Alzheimer's Disease (Phase 1) | Oligomerix, Inc. | Tau | Small Molecule | ||
| PNT001 | Alzheimer's Disease (Inactive), Traumatic Brain Injury (Inactive) | Pinteon Therapeutics | Tau | Immunotherapy (passive) | ||
| Posdinemab | JNJ-63733657 | Mild AD (Phase 2) | Janssen | Tau | Immunotherapy (passive) | |
| Rember TM | Methylene Blue , methylthioninium (MT), TRx-0014, Tau aggregation inhibitor (TAI) |
Alzheimer's Disease (Discontinued) | TauRx Therapeutics Ltd | Tau | Small Molecule | Methylene Blue predates FDA. Used for treatment of malaria and methemoglobinemia. |
| RG7345 | RO6926496 | Alzheimer's Disease (Discontinued) | Tau | Immunotherapy (passive) | ||
| Semorinemab | RO7105705 , MTAU9937A, RG6100 |
Alzheimer's Disease (Inactive) | AC Immune SA, Genentech, Hoffmann-La Roche | Tau | Immunotherapy (passive) | |
| Tideglusib | NP031112, Nypta® , Zentylor™ , Glycogen synthase kinase 3 inhibitor, NP12 |
Alzheimer's Disease (Discontinued), Progressive Supranuclear Palsy (Discontinued) | Zeltia Group | Tau | Small Molecule | |
| Tilavonemab | ABBV-8E12, C2N 8E12, HJ8.5 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | AbbVie, C2N Diagnostics, LLC | Tau | Immunotherapy (passive) | |
| TPI 287 | Alzheimer's Disease (Inactive), Corticobasal Degeneration (Inactive), Progressive Supranuclear Palsy (Phase 1) | Cortice Biosciences | Tau | Small Molecule | ||
| VY-TAU01 | HC3LC2, Voyager_9 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) | |
| Zagotenemab | LY3303560 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Tau, Unknown | Immunotherapy (passive) |